Phio Pharmaceuticals Corp. (PHIO)
PHIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.8399
+0.0327 (+4.05%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $10.04m
- P/E
- –
- EPS, last 4 quarters
- $-1.21
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7500 to $1.88
- Average volume
- 102.6k
- Previous close
- $0.8072
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $14.00, +1566.9% from here
Earnings
next estimate $-0.3900Next report
Dec 2025
+55.9%
Mar 2026
-41.7%
Jun 2026
0.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.50m | -$2.53m | -$4.17m | -$4.27m |
| Net income | -$2.39m | -$2.37m | -$4.00m | -$4.14m |
News
8 latest- Phio Secures Additional Patent Protection In US, Canada, Japan For INTASYL Compounds RTTNews · Jul 17, 2026
- Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace RTTNews · Feb 13, 2026
- Phio Pharmaceuticals Reports Positive Safety Review Of PH-762 In Skin Cancer Trial RTTNews · Feb 11, 2026
- Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026 RTTNews · Dec 24, 2025
- Phio Pharmaceuticals Stock Falls 5% Amid Financing And Clinical Updates RTTNews · Nov 3, 2025
- Biotech Stocks Rally After Hours On Trial Progress And Key Updates RTTNews · Sep 30, 2025
- Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz RTTNews · Sep 10, 2025
- Phio Posts Wider Loss in Fiscal Q2The Motley Fool · Aug 14, 2025
The company
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- phiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.